CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,724,648
- in 7 filings, $2.7M under 10b5-1 plans
Net −$2,724,648. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-17 | THEUER CHARLES Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-17 | Miller-Rich Nancy Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-17 | MILLIGAN JOHN F Director | Grant or award · Stock Option (Right to Buy) | +33,750 | 33,750 | ||
| 2025-03-06 | Bizily Scott Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +78,500 | 78,500 | ||
| 2025-03-06 | Kirn David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +267,500 | 267,500 | ||
| 2025-03-06 | Kim Robert Young Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +92,300 | 92,300 | ||
| 2025-03-06 | Mehra Uneek See Remarks | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2025-03-06 | Kamal Fariborz President & COO | Grant or award · Stock Option (Right to Buy) | +178,400 | 178,400 | ||
| 2024-12-09 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other disposition | −535,000 | 4,563,211 | ||
| 2024-12-09 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other acquisition · Pre-Funded Warrants (Right to Buy) | +535,000 | 3,610,000 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other disposition | −3,062,000 | 830,237 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other disposition | −2,378,000 | 662,970 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other disposition | −240,000 | 87,911 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other acquisition · Pre-Funded Warrant | +3,062,000 | 3,062,000 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other acquisition · Pre-Funded Warrant | +2,378,000 | 2,378,000 | ||
| 2024-11-08 | BVF PARTNERS L P/IL See Explanation of Responses | Other acquisition · Pre-Funded Warrant | +240,000 | 240,000 | ||
| 2024-09-16 | Bizily Scott Chief Legal Officer | Option exercise 10b5-1 | +500 | $6.49 | $3K | 7,281 |
| 2024-09-16 | Bizily Scott Chief Legal Officer | Sale 10b5-1 | −500 | $16.33 | $8K | 6,781 |
| 2024-09-16 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right To Buy) 10b5-1 | −500 | 10,379 | ||
| 2024-08-19 | Bizily Scott Chief Legal Officer | Option exercise 10b5-1 | +500 | $6.49 | $3K | 7,281 |
Page 5 of 16 · 319 trades